Codiak Biosciences
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Codiak Biosciences was a Cambridge, Massachusetts-based clinical-stage biotech pioneering exosome-based therapeutics - engineering drug molecules into exosomes, the cell's intercellular delivery vesicles, to reach disease targets including tumors. Based on research from the University of Gothenburg and MD Anderson Cancer Center via Flagship Pioneering, the company built the engEx engineering and manufacturing platform and advanced two candidates into the clinic: exoSTING for solid tumors (phase 1/2) and exoIL-12 for early-stage cutaneous T cell lymphoma (phase 1).
02 / Codiak Biosciences FAILURE REASONS
Failure factors supported by the current evidence
Fierce Biotech (27 Mar 2023) reports Codiak filed bankruptcy restructuring after the board said a structured sale process was the best option given the company’s financial needs and clinical-stage pipeline; the article notes $51.8 million cash at end-September against a $19.3 million quarterly loss, meaning it would have needed significant new funding to continue as a going concern, after 2022 layoffs and paused Phase 2 plans.
Fierce Biotech said Codiak would have needed significant funding to plug the gap between $51.8 million cash (end-September) and a $19.3 million quarterly loss to continue as a going concern.
CEO Douglas Williams said the bankruptcy restructuring sale process was chosen after assessing strategic options in light of Codiak’s financial needs.
The article recounts August layoffs of over a third of staff and paused Phase 2 launches for exoSTING and exoIL-12.
03 / EVENT HISTORY
Events in the structured record
- Asset restructuring
Codiak’s 27 Mar 2023 Form 8-K states a voluntary bankruptcy restructuring petition in Delaware (Case No. 23-10350) and that the company intends to sell substantially all assets in the case, after a 23 Mar 2023 board-approved 69% workforce cut.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Founded in 2015; raised approximately $257.4 million in total.
- 02
On October 14, 2020 it IPO'd on Nasdaq (ticker CDAK), issuing 5.5 million shares at $15 for gross proceeds of about $82.5 million (about $74.4 million net).
- 03
Lead candidates exoSTING (solid tumors) and exoIL-12 (early cutaneous T-cell lymphoma) both reached the clinic under CEO Douglas Williams.
- 04
No material audited loss was publicly disclosed (net losses reflect routine R&D spending).